• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Training and Continuing Education

  • Print
  • Share
  • E-mail

FDA Continuing Education Programs on Medscape

 

As part of a collaboration between FDA and Medscape disclaimer icon, a series of Continuing Education activities are available to communicate important safety information to clinicians. Featuring FDA experts, these CME/CE certified courses cover a range of topics related to FDA's multi-faceted mission of protecting and promoting the public health by ensuring the safety and quality of medical products such as drugs, foods, and medical devices.

The complete terms and framework of the partnership with Medscape are described in the Memorandum of Understanding.

 

Continuing Education Programs

 The Bad Ad Program and Prescription Drug Promotion CME 

The Bad Ad Program and Prescription Drug Promotion disclaimer icon 
http://www.sigmatech.com/BadAd/ disclaimer icon

The goal of this activity is to educate healthcare professionals and students about the role they can play in helping the FDA ensure that prescription drug advertising and promotion is truthful and not misleading.

October 2013

 

Melissa M. Truffa, BSPharm, Associate Director, Division of Pharmacovigilance, FDA Office of Surveillance and Epidemiology

Tell It to the FDA: The Adverse Drug Event Case Report disclaimer icon http://www.medscape.org/viewarticle/773104 disclaimer icon

Featuring Melissa M. Truffa, BSPharm, Associate Director, Division of Pharmacovigilance, FDA Office of Surveillance and Epidemiology, and Anna Fine, PharmD, Director, Health Professional Liaison Program, FDA Office of Special Health Issues. Learn how to prepare a relevant narrative to describe the adverse event in your case report for the FDA’s MedWatch system.

October 2012

Anna Fine, PharmD, Director, Health Professional Liaison Program, FDA Office of Special Health Issues 

Your Patient Has an Adverse Reaction to a Drug: How to Report to FDA's MedWatch disclaimer icon
http://www.medscape.org/viewarticle/766272 disclaimer icon

Featuring Anna Fine, PharmD, Director, Health Professional Liaison Program, FDA Office of Special Health Issues. Learn how to identify the types of adverse events and product problems or errors that should be reported to FDA.

July 2012

Panel discussion for REMS Program for Transmucosal Immediate-Release Fentanyl Products 

REMS Program for the Transmucosal Immediate-Release Fentanyl Products disclaimer icon
http://www.medscape.org/viewarticle/765473 disclaimer icon 

Panel discussion featuring Theresa A. Toigo, RPh, MBA (Associate Director, Drug Safety Operations, FDA) and Sharon Hertz, MD (Deputy Director, Division of Anesthesia, Analgesia, and Addiction Products, FDA). 

This CME/CE activity will explain why a risk evaluation and mitigation strategy (REMS) is needed to ensure safe and effective use of the transmucosal immediate-release fentanyl products.

July 2012

 Panel discussion moderated by Claudia Karwoski, Director, Division of Risk Management, CDER

Risk Evaluation and Mitigation Strategies: An Introduction for Physicians, Nurses, and Pharmacists disclaimer icon 
http://www.medscape.org/viewarticle/762673 disclaimer icon  

Panel discussion moderated by Claudia Karwoski, PharmD, Director, Division of Risk Management, FDA Center for Drug Evaluation and Research. This CME/CE activity addresses the use of risk evaluation and mitigation strategies, an important and evolving topic that has wide-reaching implications for physicians, nurses, and pharmacists.  

May 2012

Panel discussion moderated by Dr. Leonard Sacks, Acting Director, FDA Office of Critical Path Programs

Transforming a Clinician Into an Investigator: What Does It Take? disclaimer icon
http://www.medscape.org/viewarticle/752701
 

Panel discussion moderated by Dr. Leonard Sacks, Acting Director, Office of Critical Path Programs at FDA. This CME/CE activity will help clarify the responsibilities of clinical investigators and address some of the challenges that investigators face today. 

November 2011

  

 

Contact FDA

301-796-8460
Office of Health and Constituent Affairs

10903 New Hampshire Avenue

Bldg. 32, Room 5367

Silver Spring, MD 20993
-